Literature DB >> 7756049

Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.

R W Boyce1, T J Wronski, D C Ebert, M L Stevens, C L Paddock, T A Youngs, H J Gundersen.   

Abstract

Newly developed unbiased stereological methods were employed to investigate the effects of estrogen deficiency on the three-dimensional connectivity of vertebral cancellous bone from ovariectomized (OVX) rats. The effects of two classes of antiresorptive agents, estrogen and bisphosphonates, on changes in connectivity in this animal model were also evaluated. Female rats were either sham-operated (sham-op) or surgically OVX at 90 days of age. OVX rats were administered either vehicle, estrogen (10 micrograms/kg 17-beta estradiol, 5 days/week subcutaneously [SC], etidronate disodium (5 mg/kg SC) or risedronate (5 micrograms/kg SC). The bisphosphonates were administered daily for 1 week followed by 3 weeks with no treatment. Treatment duration was 360 days. Systematic random sections, 30-microns thick, were prepared from methylmethacrylate-embedded decalcified second lumbar vertebrae. Total trabecular number and connectivity density were estimated using the ConnEulor principle. Vertebral cancellous bone volume was estimated on undecalcified sections from the first lumbar vertebrae. Connectivity density and cancellous bone volume were significantly reduced (approximately 25% and 40%, respectively) in the OVX group compared with the sham-op group. Estrogen treatment essentially maintained connectivity and cancellous bone volume at the level of the sham-op rats. Connectivity density and total trabecular number were significantly increased in the etidronate- and risedronate-treated rats compared with both the sham-op and OVX rats. These data demonstrate that reduction in the three-dimensional connectivity of vertebral cancellous bone is a long-term consequence of ovariectomy in the rat. This reduction in connectivity can be effectively prevented by the administration of antiresorptive agents such as estrogen, etidronate and risedronate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756049     DOI: 10.1016/8756-3282(94)00031-t

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

1.  Micro-CT and mechanical evaluation of subchondral trabecular bone structure between postmenopausal women with osteoarthritis and osteoporosis.

Authors:  Z-M Zhang; Z-C Li; L-S Jiang; S-D Jiang; L-Y Dai
Journal:  Osteoporos Int       Date:  2009-09-22       Impact factor: 4.507

2.  Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants.

Authors:  S D Bain; C Jerome; V Shen; I Dupin-Roger; P Ammann
Journal:  Osteoporos Int       Date:  2008-12-19       Impact factor: 4.507

Review 3.  Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.

Authors:  Solomon Epstein
Journal:  Curr Osteoporos Rep       Date:  2006-03       Impact factor: 5.096

Review 4.  Risedronate.

Authors:  K L Goa; J A Balfour
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

Review 5.  Bisphosphonate mechanism of action.

Authors:  Alfred A Reszka; Gideon A Rodan
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

6.  The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

Authors:  Ayako Shiraishi; Sayaka Miyabe; Takayoshi Nakano; Yukichi Umakoshi; Masako Ito; Masahiko Mihara
Journal:  BMC Musculoskelet Disord       Date:  2009-06-15       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.